Project Grant R21EY036503
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$185K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Fort Worth, TX 76107, USA
Similar Awards
This $568,122 Project Grant from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research at Baylor College of Medicine to unequivocally confirm the contribution of neurovascular dysfunction to glaucoma pathogenesis and identify endothelial cell-specific ligands with potential for neuroprotective therapy. The research aims to globally map all ligands binding to ocular hypertension and healthy retinal cells, quantify their binding activities, and...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This federal Project Grant award of $362,415 from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of the orexin neurotransmitter system in regulating intraocular pressure (IOP) and its potential implications for glaucoma treatment. The research aims to: 1) examine the influence of the brainstem raphe pallidus on IOP elevations induced by stimulation of the dorsomedial hypothalamus/perifornical region, 2) assess the...
This federal Project Grant award, totaling $496,633, was awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867). The grant supports a research project at Duke University to investigate the role of glypicans, specifically glypican-4 (GPC4), in trabecular meshwork function, intraocular pressure regulation, and the development of glaucoma. The project aims to uncover the molecular mechanisms by which augmented GPC4 expression and secretion may dysregulate Wnt...
This $526,841 Project Grant award, provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), aims to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The principal investigator at Vanderbilt University Medical Center will conduct research to determine how disruptions in cGMP signaling pathways impact retinal astrocyte and vascular networks, leading to retinal ganglion cell (RGC) metabolic stress and axon degeneration in glaucoma. The...
The National Eye Institute (NEI) awarded a $425,000 Project Grant (CFDA 93.867 - Vision Research) to the Massachusetts Eye and Ear Infirmary to conduct large-scale genetic profiling of childhood glaucoma in India. The project aims to identify causal mutations in known childhood glaucoma genes and discover novel genes responsible for this debilitating disease. The research will leverage whole exome sequencing data from 480 childhood glaucoma patients and family members in India to apply quality...
This $661,635 Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) supports research to elucidate the molecular changes in the extracellular matrix (ECM) of the outflow pathway that regulate intraocular pressure in steroid-induced ocular hypertension and open-angle glaucoma. The award recipient, The Research Foundation for the State University of New York (RFSUNY), will employ a biomimetic artificial conventional outflow system...
This federal Project Grant award under the National Eye Institute (NEI) Vision Research program (CFDA 93.867) provides $191,095 to The University of North Texas Health Science Center at Fort Worth (UNTHSC) for research on understanding how metabolic changes in optic nerve head cells contribute to fibrosis and retinal ganglion cell axon loss in glaucoma. The key objectives are to: 1) Establish that glutaminolysis, a metabolic pathway, is driven by YAP/TAZ signaling in optic nerve head...
The National Eye Institute (NEI) awarded a $679,159 Project Grant (CFDA 93.867 - Vision Research) to The Schepens Eye Research Institute, Inc. to investigate the combined effects of aging and elevated intraocular pressure (IOP) on the development of glaucoma and the retinal ganglion cell (RGC) transcriptome. The research aims to: 1) Demonstrate that elevated IOP-induced glaucoma is more severe in aging mice and that transient AAV2-OSK (Oct4, Sox2, Klf4) mediated epigenetic reprogramming can...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), will support research to investigate the molecular mechanisms underlying trabecular meshwork cell loss and cytotoxicity caused by mutant myocilin misfolding in glaucoma. The $447,479 award to Georgia TECH Research Corp will enable a 5-year research project to: 1) Screen a yeast gene deletion library to identify genes that can restore cell viability when mutant myocilin is expressed,...